Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reversal through TRH of opioid-induced respiratory depression (OIRD) in healthy volunteers
2017-004973-15Phase 4Terminated
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, single-arm trial of thyrotropin-releasing hormone in opioid-induced respiratory depression (OIRD) and hypopnea, sponsored by Leiden University Medical Center. Primary endpoint: Ventilation increase following opioid-induced respiratory depression. Started Mar 2018; status: terminated.
02
Drugs
thyrotropin-releasing hormone
03
Conditions
opioid-induced respiratory depression (OIRD)hypopnea
Beyond the preview
Go deeper on 2017-004973-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004973-15.